The objective of this study is to determine if an intervention with a fracture manager to arrange bone densitometry after hip fracture is more effective in diagnosing and treating osteoporosis than compared to "usual care". "Usual care" consists of no intervention to arrange BMD testing or therapy other than what normally occurs in the community. We postulate that a fracture manager will be more effective in getting BMD done and in starting appropriate therapy.

Condition	Intervention	Phase
Osteoporosis Hip Fracture	Procedure: bone densitometry (DEXA)  Drug: alendronate or risedronate	Phase III

Further Study Details: 

Expected Total Enrollment:  250

All hip fracture patients in the Edmonton area will be screened for eligibility (mini-mental status >20, not on active osteoporosis pharmacologic therapy). All patients will have informed consent obtained. Patients will be randomized to 2 groups:

1. Group 1 . Active intervention. The fracture manager will arrange for bone densitometry (DEXA) to be done 3-6 months after the fracture. If the patient meets standard criteria for osteoporosis, therapy with a bisphosphonate (alendronate or risedronate) will be instituted by the study physicians.
2. Group 2. Usual care. Patients will receive basic information about calcium and vitamin D and osteoporosis and told to follow up with their family doctor. At 6 months, patients will be contacted to determine if they have had a BMD done or started on active (drug) osteoporosis therapy. If not, the fracture manager will arrange the BMD and if appropriate therapy will be started by the study physicians.

All patients will be followed for 1 year. The primary endpoints are the number of patients who get a BMD and the number who are started on active osteoporosis therapy.

Ages Eligible for Study:  50 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Age 50 or over, male or female
• Reside in the community or have access to bone densitometry
• Hip fracture
• Patient can consent or proxy consent available
• No contraindications to bisphosphonates

Exclusion Criteria:

• Patient refuses consent process
• Already receiving active drug therapy for osteoporosis other than calcium and vitamin D
• Dementia or delirium
• pathological fracture
• Chronic corticosteroid therapy

Canada, Alberta
      University of Alberta, Edmonton,  Alberta,  T6G2S2,  Canada

Study chairs or principal investigators

Donald W Morrish, MD, PhD,  Principal Investigator,  University of Alberta   

Study ID Numbers:  Hipfracture1; AHFMR 200100791-2
Last Updated:  August 25, 2005
Record first received:  August 25, 2005
ClinicalTrials.gov Identifier:  NCT00136058
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2005-08-30